Of note, CCl4-induced liver fibrosis was significantly worse at 8 weeks (Figure 9D-H) than at 6 weeks (Figure 8), while AAV8-shTinagl1 significantly reduced the degree of liver fibrosis (Figure 9D) and the liver / body weight ratio (Figure 9E), significantly reduced liver hydroxyproline content (Figure 9F) and serum levels of ALT and AST (Figure 9G), and decreased fibrotic factors, proinflammatory cytokines, and PDGFRβ at mRNA and protein levels (Figure 9H) compared to the CCl4-injected group. The gene discussed is PDGFRB; the disease is Hepatic fibrosis.